Payment overview · 2025
General Payments
$538.19
31 reported records · 9 companies
Healthcare provider profile · identity verified
William S Cole, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1346229820
Verified facts
What the public records show
CMS Open Payments records show William S Cole, M.D. received $538.19 in general payments during 2025 across 31 reported records.
Dexcom, Inc. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $139.55 | 25.9% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $125.00 | 23.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.24 | 12.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.73 | 11.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.12 | 10.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.68 | 5.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.46 | 4.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.42 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $522.20 | 30 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $139.55 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.12 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $44.68 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 605 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 137 |
| Losartan Potassium | Losartan Potassium | 362 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 89 |
| Lisinopril | Lisinopril | 340 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 313 | 82 |
| Omeprazole | Omeprazole | 245 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 49 |
| Metformin Hcl | Metformin Hcl | 212 | 62 |
| Gabapentin | Gabapentin | 204 | 54 |
| Tramadol Hcl | Tramadol Hcl | 191 | 54 |
| Potassium Chloride | Potassium Chloride | 189 | 51 |
| Alprazolam | Alprazolam | 186 | 39 |
| Furosemide | Furosemide | 159 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 145 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 37 |
| Sertraline Hcl | Sertraline Hcl | 142 | 37 |
| Meloxicam | Meloxicam | 140 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 47 |
| Lorazepam | Lorazepam | 127 | 23 |
| Trazodone Hcl | Trazodone Hcl | 111 | 32 |
| Donepezil Hcl | Donepezil Hcl | 110 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 26 |
| Carvedilol | Carvedilol | 107 | 24 |
| Allopurinol | Allopurinol | 106 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 23 |
| Buspirone Hcl | Buspirone Hcl | 102 | 21 |
| Temazepam | Temazepam | 101 | 14 |
| Glimepiride | Glimepiride | 95 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 27 |
| Ezetimibe | Ezetimibe | 93 | 27 |
| Famotidine | Famotidine | 93 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 26 |
| Eliquis | Apixaban | 92 | 19 |
| Ozempic | Semaglutide | 91 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 18 |
| Simvastatin | Simvastatin | 80 | 19 |
| Methylprednisolone | Methylprednisolone | 79 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 18 |
| Valsartan | Valsartan | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 11 |
| Pregabalin | Pregabalin | 71 | 15 |
| Clonazepam | Clonazepam | 69 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 16 |
| Ondansetron Odt | Ondansetron | 69 | 38 |
| Montelukast Sodium | Montelukast Sodium | 68 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 12 |
| Alendronate Sodium | Alendronate Sodium | 63 | 20 |
| Metformin Hcl Er | Metformin Hcl | 59 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 19 |
| Lovastatin | Lovastatin | 58 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 12 |
| Synthroid | Levothyroxine Sodium | 56 | 13 |
| Azithromycin | Azithromycin | 55 | 48 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 15 |
| Bumetanide | Bumetanide | 45 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 15 |
| Spironolactone | Spironolactone | 41 | 13 |
| Cephalexin | Cephalexin | 38 | 33 |
| Clonidine Hcl | Clonidine Hcl | 36 | 12 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 29 |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 28 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Gemtesa | Vibegron | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.19 · 31 records | Dexcom, Inc. | Auvelity, BREZTRI, CARDIOMEMS, Dexcom G6 Transmitter, KISUNLA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error